Elanco Animal Health (NYSE:ELAN – Get Free Report) and Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.
Profitability
This table compares Elanco Animal Health and Unicycive Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Elanco Animal Health | -3.96% | 8.13% | 3.99% |
| Unicycive Therapeutics | N/A | -91.50% | -61.47% |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Elanco Animal Health and Unicycive Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Elanco Animal Health | 1 | 2 | 8 | 1 | 2.75 |
| Unicycive Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
Risk & Volatility
Elanco Animal Health has a beta of 1.68, suggesting that its stock price is 68% more volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 1.79, suggesting that its stock price is 79% more volatile than the S&P 500.
Institutional and Insider Ownership
97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by company insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Elanco Animal Health and Unicycive Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Elanco Animal Health | $5.02 billion | 2.24 | -$232.00 million | ($0.41) | -54.93 |
| Unicycive Therapeutics | $680,000.00 | 194.54 | -$26.56 million | ($1.75) | -2.71 |
Unicycive Therapeutics has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Elanco Animal Health beats Unicycive Therapeutics on 8 of the 15 factors compared between the two stocks.
About Elanco Animal Health
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
